All In Biotech

Drug Trial Radar · NCT06300307

Study of ATX-01 in Participants With DM1

A Phase 1/2a Double-Blind, Placebo-controlled, Single- and Multiple Ascending Dose Study to Assess the Safety, Tolerability, PK, PD and Efficacy of IV Administration of ATX-01 In Male and Female Participants Aged 18 to 64 With Classic DM1

Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

56

Planned (sponsor's estimate)

Start

Oct 15, 2024

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
ARTHEx Biotech S.L.Industry
Sponsor type
Industry
First posted
Mar 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to test ATX-01 in participants with myotonic dystrophy type 1 (DM1). The main question it aims to answer is if ATX-01 is safe and well tolerated. The trial will compare the safety and tolerability of ATX-01 and a matching placebo. There will be a single-ascending dose part of the trial and a multiple-ascending dose part. In the single-ascending dose, participants will receive one dose of ATX-01 or placebo. In the multiple-ascending dose part, participants will receive three doses of ATX-01 or placebo. ATX-01 is a novel anti-miR (synthetic single stranded oligonucleotide) that inhibits a microRNA called miR-23b.

Conditions

  • Myotonic Dystrophy 1

Interventions

  • ATX-01Drug

    Solution for infusion

  • PlaceboDrug

    Solution for infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventsTime frame: Up to 120 days

Locations

12 sites in 7 countries. Site status is shown where the registry gives one.

  • UCLA

    Los Angeles, California · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • University of Iowa Health Care - Department of Neurology

    Iowa City, Iowa · Recruiting

  • University of Kansas Medical Center, Department of Neurology

    Fairway, Kansas · Recruiting

  • Virginia Commonwealth University

    Richmond, Virginia · Recruiting

  • Centre Intégré Universitaire de Santé et Services Sociaux du Saguenay-Lac-St-Jean

    Chicoutimi, Quebec, Canada · Recruiting

  • Institute of Myology

    Paris, France · Recruiting

  • The NeMO Clinical Center in Milan, Neurorehabilitation Unit, University of Milan

    Milan, Italy · Recruiting

  • Fondazione Policlinico A. Gemelli- IRCCS

    Rome, Italy · Recruiting

  • Radboudumc

    Nijmegen, Netherlands · Recruiting

  • Hospital Universitario Donostia

    Donostia / San Sebastian, Spain · Recruiting

  • St. George's University Hospital

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.